These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15017568)

  • 1. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease.
    Arthur GL; Schwartz MZ; Kuenzler KA; Birbe R
    J Pediatr Surg; 2004 Mar; 39(3):448-52; discussion 448-52. PubMed ID: 15017568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease.
    Arthur LG; Schwartz MZ; Kuenzler KA; Birbe R
    J Pediatr Surg; 2004 Feb; 39(2):139-43; discussion 139-43. PubMed ID: 14966727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.
    Alavi K; Schwartz MZ; Palazzo JP; Prasad R
    J Pediatr Surg; 2000 Jun; 35(6):847-51. PubMed ID: 10873024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte growth factor ameliorates inflammatory bowel disease in a rat model.
    Arthur LG; Kuenzler KA; Schwartz MZ
    J Gastrointest Surg; 2003 Dec; 7(8):1062-8; discsussion 1068. PubMed ID: 14675716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion.
    Prasad R; Alavi K; Schwartz MZ
    J Pediatr Surg; 2001 Apr; 36(4):570-2. PubMed ID: 11283879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion.
    Prasad R; Alavi K; Schwartz MZ
    J Pediatr Surg; 2000 Feb; 35(2):357-9. PubMed ID: 10693696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury.
    Rajeevprasad R; Alavi K; Schwartz MZ
    J Pediatr Surg; 2000 Nov; 35(11):1537-9. PubMed ID: 11083417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth factor manipulation of intestinal angiogenesis: a possible new paradigm in the management of inflammatory bowel disease.
    Thatch KA; Mendelson KG; Haber MM; Schwartz MZ
    J Surg Res; 2009 Oct; 156(2):245-9. PubMed ID: 19524260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats.
    Washizawa N; Gu LH; Gu L; Openo KP; Jones DP; Ziegler TR
    JPEN J Parenter Enteral Nutr; 2004; 28(6):399-409. PubMed ID: 15568286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo.
    Kato Y; Yu D; Schwartz MZ
    J Pediatr Surg; 1999 Jan; 34(1):18-20; discussion 20-1. PubMed ID: 10022136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.
    Bertrand V; Quéré S; Guimbaud R; Sogni P; Chauvelot-Moachon L; Tulliez M; Lamarque D; Charreire J; Giroud JP; Couturier D; Chaussade S; Breban M
    Eur Cytokine Netw; 1998 Jun; 9(2):161-70. PubMed ID: 9681392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease.
    Peterson RL; Wang L; Albert L; Marchese E; Erickson J; Wong A; Mounts WM; Hayes L; Bouchard P; Keith J; Dorner AJ
    Pharmacogenomics J; 2002; 2(6):383-99. PubMed ID: 12629504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased tissue protein synthesis during spontaneous inflammatory bowel disease in HLA-B27 rats.
    El Yousfi M; Breuillé D; Papet I; Blum S; André M; Mosoni L; Denis P; Buffière C; Obled C
    Clin Sci (Lond); 2003 Oct; 105(4):437-46. PubMed ID: 12793856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats.
    Aiko S; Grisham MB
    Gastroenterology; 1995 Jul; 109(1):142-50. PubMed ID: 7797013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease.
    Hammer RE; Richardson JA; Simmons WA; White AL; Breban M; Taurog JD
    J Investig Med; 1995 Jun; 43(3):262-8. PubMed ID: 7614072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum.
    Sigalet DL; Bawazir O; Martin GR; Wallace LE; Zaharko G; Miller A; Zubaidi A
    Dig Dis Sci; 2006 Sep; 51(9):1557-66. PubMed ID: 16927140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats.
    Milia AF; Manetti M; Generini S; Polidori L; Benelli G; Cinelli M; Messerini L; Ibba-Manneschi L; Matucci-Cerinic M
    J Cell Mol Med; 2009 Jan; 13(1):164-76. PubMed ID: 18363845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven.
    Rauner M; Thiele S; Fert I; Araujo LM; Layh-Schmitt G; Colbert RA; Hofbauer C; Bernhardt R; Bürki A; Schwiedrzik J; Zysset PK; Pietschmann P; Taurog JD; Breban M; Hofbauer LC
    Bone; 2015 Jun; 75():183-91. PubMed ID: 25746795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated measurement of intestinal permeability as an assessment of colitis severity in HLA-B27 transgenic rats.
    Kerr SW; Wolyniec WW; Filipovic Z; Nodop SG; Braza F; Winquist RJ; Noonan TC
    J Pharmacol Exp Ther; 1999 Nov; 291(2):903-10. PubMed ID: 10525115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.
    Martin GR; Wallace LE; Sigalet DL
    Am J Physiol Gastrointest Liver Physiol; 2004 Jun; 286(6):G964-72. PubMed ID: 14962847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.